fluocinolone acetonide has been researched along with Central Retinal Edema, Cystoid in 132 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (6.82) | 29.6817 |
| 2010's | 73 (55.30) | 24.3611 |
| 2020's | 50 (37.88) | 2.80 |
| Authors | Studies |
|---|---|
| Adán, A; Figueras-Roca, M; Miguel-Escuder, L; Moll-Udina, A; Navarro-Angulo, MJ; Olate-Pérez, Á; Pelegrín, L; Sala-Puigdoners, A | 1 |
| Clemmensen, KØ; Nielsen, MS; Studsgaard, A | 1 |
| Coughlin, B; Gonzalez, VH; Mansour, SE; Sheth, V; Singer, MA | 1 |
| Beirão, JM; Castro, C; Ferreira, A; Figueira, J; Heitor, J; Leite, J; Meireles, A; Menéres, P; Pessoa, B | 1 |
| Bandello, F; Behar-Cohen, F; Bilgic, A; Cunha-Vaz, J; de Smet, M; Dirven, W; Dot, C; Kodjikian, L; Loewenstein, A; Mathis, T; Sudhalkar, A; Zarranz-Ventura, J | 1 |
| Ackermann, H; Chedid, A; Deuchler, SK; Kenikstul, N; Koch, F; Kohnen, T; Schubert, R; Scott, J; Singh, P | 1 |
| Herold, TR; Koenig, SF; Liegl, R; Priglinger, SG; Vounotrypidis, E; Wolf, A | 1 |
| Cox, L; Fotuhi, M; Hamilton, RD; Li, Y; Lukic, M; Rajendram, R; Vermeirsch, S; Yeung, I | 1 |
| Ghaffour, Y; Soler, V; Varenne, F | 1 |
| Bailey, C; Castro de Sousa, JP; Chakravarthy, U; Hill, L; Khoramnia, R; Koch, F; Peto, T; Taylor, SR | 1 |
| Grigorian, R; Holekamp, N; Kasper, J; Merrill, PT; Roth, D | 1 |
| Chavan, R; Dobler, E; Lip, PL; Mitra, A; Mohammed, BR; Mushtaq, B | 1 |
| Diago, T; Fau, SG; Roca, JM | 1 |
| Azar, M; Delyfer, MN; Gattoussi, S; Gontier, B; Jomaa, E; Korobelnik, JF; Koudsié, S; Rougier, MB; Seguy, PH | 1 |
| Avogaro, F; Calandri, A; Florido, A; Toja, F; Vingolo, EM | 1 |
| Eichenbaum, DA; Hariprasad, SM; Kiernan, DF; Kolomeyer, AM; Suñer, IJ | 1 |
| Gatzioufas, Z; Motta, L; Mushtaq, MM; Mushtaq, Y; Panos, GD; Ripa, M | 1 |
| Oakey, ZB; Singaravelu, J; Singh, AD; Wrenn, JM | 1 |
| Fernández-Hernández, R; Rustullet-Olivé, M; Vilaplana-Blanch, D | 1 |
| Almeida, DRP; Coughlin, B; Cutino, A; Gonzalez, VH; Kasper, J; Kiernan, DF; Luo, C | 1 |
| Abbey, AM; Flores, J; Patel, KG | 1 |
| Abdin, AD; Löw, U; Munteanu, C; Seitz, B; Wykrota, AA | 1 |
| Bakri, SJ; Shah, SM | 1 |
| Adán, A; Coelho-Borges, AI; Hernanz, I; Llorenç, V; Moll-Udina, A; Pazos, M; Pelegrín, L; Sainz-de-la-Maza, M | 1 |
| Bandello, F; Borrelli, E; Corbelli, E; Giuffrè, C; Querques, G; Sacconi, R | 1 |
| Busch, C; Jochmann, C; Rehak, M; Unterlauft, JD; Wiedemann, P | 1 |
| Castro-de-Sousa, JP; Kaku, P; Marques-Neves, C; Martins, D; Nascimento, J; Prates Canelas, J; Reis, P; Sampaio, A; Urbano, H; Vaz-Pereira, S | 1 |
| Arruti, N; Panos, GD; Patra, S | 1 |
| Cai, CX; Grewal, DS; Jaffe, GJ; Keenan, RT; Skalak, C | 1 |
| Bandello, F; Capone, L; Cicinelli, MV; Lattanzio, R; Rabiolo, A; Zollet, P | 1 |
| Currie, CJ; Habib, M; Holden, SE | 1 |
| Eichenbaum, D; Holekamp, NM; Kaba, S; Kiernan, DF; Mansour, SE; Roth, DB; Werts, E | 1 |
| Cutino, A; Eaton, AM; Riemann, CD | 1 |
| Ciernik, IF; Grajewski, L; Kneifel, C; Krause, L; Zimmermann, L | 1 |
| Altaweel, MM; Burke, AE; Holbrook, JT; Jabs, DA; Jaffe, GJ; Kempen, JH; Lightman, SL; Lim, LL; Sugar, EA; Tomkins-Netzer, O | 1 |
| Li, T; Mir, TA; Rittiphairoj, T; Virgili, G | 1 |
| Grewal, DS; Singer, MA; Wykoff, CC | 1 |
| Ajamil-Rodanes, S; Luis, J; Pavesio, C; Robson, AG; Testi, I; Westcott, M | 1 |
| Elbarky, AM | 1 |
| Cabral, D; Costa, J; Ferreira, JT; Luís, ME; Sampaio, F; Teixeira, C | 1 |
| Bandello, F; Capone, L; Cicinelli, MV; Grosso, D; Lattanzio, R; Loewenstein, A; Rabiolo, A; Rosenblatt, A; Zollet, P | 1 |
| Beirão, JM; Ferreira, A; Figueira, J; Leite, J; Meireles, A; Pessoa, B | 1 |
| Ashurov, A; Chronopoulos, A; Chronopoulos, P; Hattenbach, LO; Korb, C; Pfeiffer, N | 1 |
| Agodi, A; Avitabile, T; Barchitta, M; Bonfiglio, V; Caselgrandi, P; Cennamo, G; Fallico, M; Furino, C; Longo, A; Lotery, A; Marolo, P; Maugeri, A; Reibaldi, M; Russo, A; Ventre, L | 1 |
| Albanesi, F; Caputo, CG; De Siena, E; De Vico, U; Falsini, B; Maceroni, M; Minnella, AM; Picardi, SM; Placidi, G; Rizzo, S | 1 |
| Bailey, C; Chakravarthy, U; Lotery, A; Menon, G; Talks, J | 2 |
| Conrath, J; Devin, F; Matonti, F; Morel, C; Morin, BR | 1 |
| Ku, JY; Mercieca, K; Yau, K | 1 |
| Diplotti, L; Lanzetta, P; Samassa, F; Sarao, V; Veritti, D | 1 |
| Berni, E; Currie, CJ; Holden, SE; Owens, DR | 1 |
| Currie, CJ; Holden, SE; Owens, DR | 3 |
| Hall, J | 1 |
| Beirão, M; Coelho, J; Correia, N; Ferreira, N; Meireles, A; Pessoa, B | 1 |
| Haritoglou, C; Neubauer, AS; Ulbig, MW | 1 |
| Denniston, AK; Fusi-Rubiano, W; Glover, N; Kidess, A; Lane, M; Manna, A; Morjaria, R; Mukherjee, C; Palmer, HE; Tsaloumas, MD | 1 |
| Immonen, I; Kotaniemi, K; Leinonen, S | 1 |
| Habib, MS | 1 |
| Chen, X; Fekrat, S; Finn, AP; Ong, SS; Thomas, AS; Walter, SD | 1 |
| Bailey, C; Ghanchi, F; Greven, CM; Gross, JG; Kapik, B; Kuppermann, BD; Miller, DM; Singer, MA | 1 |
| Bailey, C; Castro de Sousa, JP; Chakravarthy, U; Koch, FHJ; Taylor, SR | 1 |
| Dadoukis, P; Massa, H; Nagar, AM; Panos, GD; Patra, S; Vergados, A | 1 |
| Aballéa, S; Beiderbeck, A; McEwan, P; Pochopien, M; Toumi, M; Zur, R | 1 |
| Sridhar, J; Venincasa, MJ | 1 |
| Augustin, AJ; Bopp, S; Duncker, T; Fechner, M; Gentsch, D; Höh, H; Holz, F; Khoramnia, R; Ksinsik, C; Neuhann, T; Sandner, D; Seitz, B; Sekundo, W; Spitzer, M; Warscher, M; Winkgen, AM | 1 |
| Hardin, J; Kaintatzis, A; Sallam, AB; Uwaydat, SH; Wang, H | 1 |
| Abràmoff, MD; Chen, Z; Folk, JC; Gerendas, BS; Lee, K; Lynch, SK; Schmidt-Erfurth, U; Wahle, A; Wykoff, CC | 1 |
| Greven, MA; Gunzenhauser, RC; John, VJ | 1 |
| Lowder, CY; Punjabi, OS; Sears, JE; Shen, BY; Singh, RP | 1 |
| Comyn, O; Hykin, PG; Lightman, SL | 1 |
| Acharya, NR; Altaweel, MM; Dunn, JP; Elner, SG; Jaffe, GJ; Kempen, JH; Lightman, SL; Sugar, EA; Thorne, JE; Vitale, AT | 1 |
| Beardsley, RM; Flaxel, CJ; Messenger, WB | 1 |
| Ciulla, TA; Harris, A; Jonescu-Cuypers, C; McIntyre, N | 1 |
| Ashton, P; Bailey, C; Billman, K; Campochiaro, P; Cunha-Vaz, J; Danis, RP; Dugel, PU; Green, K; Holz, FG; Iezzi, R; Kane, F; Kapik, B; Kuppermann, BD; Weber, M | 1 |
| Bandello, F; Lattanzio, R; Preziosa, C; Querques, G | 1 |
| Behar-Cohen, F; Soubrane, G | 1 |
| Callanan, D; Itty, S; Jaffe, GJ; Jones, R; Martel, J; Pecen, P | 1 |
| Cutino, A; Green, K; Kendall, R; Moore, PT; Zachary, C | 1 |
| Agarwal, A; Do, DV; Hanout, M; Nguyen, QD; Sadiq, MA; Sarwar, S; Soliman, MK | 1 |
| Bailey, C; Baker, C; Dugel, P; Eter, N; Holz, FG; Kiss, S; Lotery, A; Menchini, U; Ruiz Moreno, JM; Weber, M; Yang, Y | 1 |
| Bailey, C; Loewenstein, A; Massin, P; Yang, Y | 1 |
| Drye, L; Holland, GN; Jabs, DA; Kempen, J; Lightman, S; Rao, NA; Stawell, RJ; Tomkins-Netzer, O; Vitale, A | 1 |
| Cáceres-del-Carpio, J; Costa, RD; Haider, A; Kuppermann, BD; Narayanan, R | 1 |
| Ciulla, TA; Hussain, RM | 1 |
| Haritoglou, C; Mayer, W; Wolf, A | 1 |
| Andreatta, W; Bhatnagar, A; Elaraoud, I; Kidess, A; Quhill, F; Tsaloumas, M; Yang, Y | 1 |
| Alfahad, Q; Elsherbiny, S; Kumar, A; Lip, PL; Mitra, A | 1 |
| Azad, S; Takkar, B | 1 |
| Puliafito, CA | 1 |
| Bacharach, J; Cousins, SW; Gonzalez, VH; Holekamp, NM; Merrill, PT; Ohr, MP; Parrish, RK; Puliafito, CA; Riemann, CD | 1 |
| Campochiaro, PA; Green, K; Parrish, RK; Pearson, PA; Traverso, CE | 1 |
| Danis, RP; Green, K; Parrish, RK; Traverso, CE | 1 |
| Chang, PY; Huang, TL; Su, PY; Wang, JK | 1 |
| Flynn, HW; Schwartz, SG; Scott, IU; Stewart, MW | 1 |
| Chaine, G; Fajnkuchen, F; Giocanti-Auregan, A; Nghiem-Buffet, S; Qu-Knafo, L; Sarda, V | 1 |
| Moisseiev, E; Morse, LS | 1 |
| Burkholder, BM; Khan, IR; Reddy, AK; Thorne, JE | 1 |
| Bailey, C; Campochiaro, PA; Chakravarthy, U; Cunha-Vaz, J; Green, K; Wykoff, CC | 1 |
| Atorf, J; Augustin, AJ; Coelho, J; El-Ghrably, I; Erginay, A; Goldsmith, C; Habib, M; Massin, P; Meireles, A; Patel, T; Pessoa, B; Tadayoni, R | 1 |
| Alfaqawi, F; Chavan, R; Elsherbiny, S; Lip, PL; Mitra, A; Mushtaq, B | 1 |
| El-Ghrably, I; Habib, M; Hillier, RJ; Manvikar, S; Steel, DHW; Vaideanu-Collins, D | 1 |
| Alves, D; Amaro, M; Cunha-Vaz, J; Figueira, J; Henriques, J; Rosas, V | 1 |
| Bailey, C; Chakravarthy, U; Downey, L; Dugel, PU; Eter, N; Ghanchi, F; Holz, FG; Lotery, A; Weber, M; Yang, Y | 1 |
| Syed, YY | 1 |
| Fekrat, S; Jaffe, GJ; Ramchandran, RS; Stinnett, SS | 1 |
| Burdan, J; Cutino, A; Green, KE; Kane, FE | 1 |
| Leedman, B | 1 |
| Montero, JA; Ruiz-Moreno, JM | 1 |
| Fujii, S; Kuno, N | 1 |
| Billman, K; Bloom, S; Brown, DM; Busquets, M; Campochiaro, PA; Ciulla, T; Feiner, L; Green, K; Hafiz, G; Kane, F; Kapik, B; Sabates, N; Shah, SM | 1 |
| Flynn, HW; Schwartz, SG | 1 |
| Fung, AE; Hung, D; Lim, JI; Wieland, M; Wong, V | 1 |
| Joussen, AM; Pleyer, U; Ruokonen, P; van der Velden, KH; Winterhalter, S | 1 |
| Billman, K; Boyer, D; Brown, DM; Campochiaro, PA; Ciulla, T; Duarte, L; Gonder, J; Gupta, A; Holz, FG; Kane, FE; Kapik, B; Madreperla, S; Pearson, A; Tolentino, M | 1 |
| Coassin, M; Hu, J; Stewart, JM | 1 |
| Hebson, CB; Srivastava, SK | 1 |
| Ashton, P; Callanan, D; Comstock, TL; Eliott, D; Ip, M; Levy, B; Mann, ES; Morse, LS; Pearson, PA | 1 |
| Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE | 1 |
| Acharya, N; Altaweel, MM; Jabs, DA; Lightman, S; Sugar, EA; Thorne, JE; Vitale, AT | 1 |
| Jaffe, GJ; Jain, N; Stinnett, SS | 1 |
| Stewart, MW | 1 |
| Bailey, C; Billman, K; Boyer, D; Brown, DM; Campochiaro, PA; Chen, S; Garretson, B; Green, K; Gupta, A; Hariprasad, SM; Kane, FE; Kapik, B; Pearson, A; Reichel, E; Ruiz-Moreno, J; Soubrane, G | 1 |
| Nentwich, MM; Ulbig, MW | 1 |
| Billman, K; Bloom, S; Brown, DM; Busquets, M; Campochiaro, PA; Ciulla, T; Feiner, L; Green, K; Hafiz, G; Kane, FE; Kapik, B; Nguyen, QD; Sabates, N | 1 |
| Sanford, M | 1 |
| Lim, LL; Rosenbaum, JT; Smith, JR | 1 |
| Lightman, S; McCluskey, P; Sivaprasad, S | 1 |
| Kaiser, PK; Lowder, CY; Singh, RP; Ufret-Vincenty, RL | 1 |
| Chong, CC; Grover, D; Li, TJ | 1 |
| Fraser-Bell, S; Hykin, PG; Kaines, A | 1 |
33 review(s) available for fluocinolone acetonide and Central Retinal Edema, Cystoid
| Article | Year |
|---|---|
Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm.
Topics: Adult; Algorithms; Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema | 2022 |
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN
Topics: Anti-Inflammatory Agents; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retinal Diseases | 2023 |
Emerging therapies in the management of macular edema: a review.
Topics: Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Dexamethasone; Diabetic Retinopathy; Fluocinolone Acetonide; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Uveitis | 2019 |
Intravitreal steroids for macular edema in diabetes.
Topics: Anti-Inflammatory Agents; Bevacizumab; Bias; Confidence Intervals; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Steroids; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2020 |
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience.
Topics: Anti-Inflammatory Agents; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema | 2021 |
Fluocinolone acetonide for the treatment of diabetic macular edema.
Topics: Cataract; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glaucoma; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Visual Acuity | 2017 |
[Cost Comparison of Licensed Intravitreal Therapies for Insufficiently Anti-VEGF Responding Fovea Involving Diabetic Macular Edema in Germany].
Topics: Cost-Benefit Analysis; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Germany; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2019 |
ILUVIEN
Topics: Angiogenesis Inhibitors; Cataract; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Delayed-Action Preparations; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Models, Economic; Quality of Life; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intravitreal Injections; Light Coagulation; Low-Level Light Therapy; Macular Edema; Patient Safety; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Ranibizumab; Retinal Vein Occlusion; Treatment Outcome; Uveitis; Visual Acuity | 2013 |
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Topics: Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intraocular Pressure; Light Coagulation; Macular Edema; Quality of Life; Triamcinolone; Vascular Endothelial Growth Factor A; Vitrectomy | 2013 |
Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Topics: Animals; Delayed-Action Preparations; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Triamcinolone Acetonide | 2014 |
Update of intravitreal steroids for the treatment of diabetic macular edema.
Topics: Diabetic Retinopathy; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Triamcinolone Acetonide | 2014 |
[Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Topics: Chronic Disease; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Edema | 2015 |
Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
Topics: Delayed-Action Preparations; Fluocinolone Acetonide; Glucocorticoids; Humans; Infusion Pumps, Implantable; Macular Edema; Treatment Outcome | 2015 |
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS.
Topics: Cataract; Dexamethasone; Diabetic Retinopathy; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Triamcinolone Acetonide; Visual Acuity | 2015 |
Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone.
Topics: Dexamethasone; Drug Delivery Systems; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Triamcinolone | 2016 |
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Bevacizumab; Dexamethasone; Diabetic Retinopathy; Drug Therapy, Combination; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2016 |
Fluocinolone acetonide for the treatment of diabetic macular edema.
Topics: Animals; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema | 2016 |
An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema.
Topics: Cataract; Dexamethasone; Diabetic Retinopathy; Fluocinolone Acetonide; Glaucoma; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects.
Topics: Diabetic Retinopathy; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2016 |
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Topics: Diabetic Retinopathy; Dose-Response Relationship, Drug; Fluocinolone Acetonide; Humans; Macular Edema; Prostheses and Implants | 2017 |
Iluvien: a new sustained delivery technology for posterior eye disease.
Topics: Delayed-Action Preparations; Diabetic Retinopathy; Fluocinolone Acetonide; Humans; Macular Edema | 2008 |
Intravitreal inserts of steroids to treat diabetic macular edema.
Topics: Dexamethasone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Triamcinolone; Vitreous Body | 2009 |
Biodegradable intraocular therapies for retinal disorders: progress to date.
Topics: Absorbable Implants; Angiogenesis Inhibitors; Clinical Trials as Topic; Dexamethasone; Diabetic Retinopathy; Drug Administration Routes; Drug Delivery Systems; Epithelial Cells; Fluocinolone Acetonide; Humans; Intraocular Pressure; Macular Degeneration; Macular Edema; Retinal Diseases; Retinal Vein Occlusion; Uveitis; Vitreous Body | 2010 |
Fluocinolone acetonide implantable device for diabetic retinopathy.
Topics: Cataract; Diabetic Retinopathy; Drug Administration Routes; Drug Delivery Systems; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitreous Body | 2011 |
[Intravitreal implants: drug carriers and carriers of hope?].
Topics: Adrenal Cortex Hormones; Chronic Disease; Dexamethasone; Diabetic Retinopathy; Drug Carriers; Drug Implants; Drug Resistance; Fluocinolone Acetonide; Humans; Immunosuppressive Agents; Macular Edema; Randomized Controlled Trials as Topic; Retinal Vein Occlusion; Secondary Prevention; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Vitreous Body | 2011 |
Corticosteroid use for diabetic macular edema: old fad or new trend?
Topics: Anti-Inflammatory Agents; Dexamethasone; Diabetic Retinopathy; Drug Administration Schedule; Drug Implants; Female; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Edema; Male; Triamcinolone; Visual Acuity | 2012 |
The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy.
Topics: Adrenal Cortex Hormones; Biological Availability; Delayed-Action Preparations; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Posterior Eye Segment; Retinal Vein Occlusion; Triamcinolone Acetonide; Uveitis, Posterior | 2012 |
Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Vitreous Body | 2013 |
Intravitreal steroids in the management of macular oedema.
Topics: Dexamethasone; Fluocinolone Acetonide; Glucocorticoids; Humans; Inflammation; Injections; Macular Edema; Retinal Vein Occlusion; Triamcinolone Acetonide; Vitreous Body | 2006 |
Intravitreal steroids for macular edema in diabetes.
Topics: Anti-Inflammatory Agents; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Injections; Macular Edema; Randomized Controlled Trials as Topic; Steroids; Triamcinolone; Visual Acuity; Vitreous Body | 2008 |
Update on treatments for diabetic macular edema.
Topics: Diabetes Complications; Enzyme Inhibitors; Fluocinolone Acetonide; Glucocorticoids; Humans; Indoles; Injections; Laser Coagulation; Macular Edema; Maleimides; Protein Kinase C; Treatment Outcome; Triamcinolone Acetonide; Vitrectomy; Vitreous Body | 2008 |
21 trial(s) available for fluocinolone acetonide and Central Retinal Edema, Cystoid
| Article | Year |
|---|---|
Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Topics: Chemokine CXCL10; Cytokines; Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Interleukin-6; Intravitreal Injections; Macular Edema; Placenta Growth Factor; Vascular Endothelial Growth Factor A; Visual Acuity | 2022 |
LONG-TERM EFFICACY OF FLUOCINOLONE IN EYES WITH IRIS-LENS DIAPHRAGM DISRUPTION AND PCME WITH MEDICATION FIXED IN THE SCLERA (MEFISTO).
Topics: Fluocinolone Acetonide; Humans; Macular Edema; Prospective Studies; Pyrimidines; Retrospective Studies; Sclera | 2022 |
Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.
Topics: Administration, Oral; Adult; Drug Implants; Epiretinal Membrane; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Uveitis; Visual Acuity | 2021 |
Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 μg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I).
Topics: Angiogenesis Inhibitors; Diabetic Retinopathy; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Male; Middle Aged; Ranibizumab; Treatment Outcome; Visual Acuity | 2018 |
Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.
Topics: Capillary Permeability; Cross-Sectional Studies; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Panuveitis; Retina; Retinal Vessels; Sensitivity and Specificity; Tomography, Optical Coherence; Uveitis, Intermediate; Uveitis, Posterior | 2013 |
Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
Topics: Aged; Anti-Inflammatory Agents; Chronic Disease; Delayed-Action Preparations; Diabetic Retinopathy; Double-Blind Method; Drug Implants; Female; Fluocinolone Acetonide; Humans; Macular Edema; Male; Middle Aged; Visual Acuity; Vitreous Body | 2014 |
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Topics: Adult; Aged; Delayed-Action Preparations; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Pseudophakia; Visual Acuity | 2015 |
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Topics: Administration, Oral; Adult; Aged; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Prednisolone; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Uveitis; Visual Acuity | 2015 |
Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
Topics: Antihypertensive Agents; Diabetic Retinopathy; Disease Management; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Ocular Hypertension; Practice Guidelines as Topic; Time Factors; Tonometry, Ocular; Trabeculectomy; Treatment Outcome; Visual Acuity; Vitreous Body | 2016 |
Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Optic Nerve; Outcome Assessment, Health Care; Treatment Outcome; Visual Acuity; Vitreous Body; Young Adult | 2016 |
Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Topics: Adult; Aged; Diabetic Retinopathy; Disease Progression; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Visual Acuity; Vitrectomy | 2017 |
A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND).
Topics: Aged; Angiogenesis Inhibitors; Chronic Disease; Delayed-Action Preparations; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Pilot Projects; Prospective Studies; Visual Acuity | 2017 |
CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Topics: Aged; Angiogenesis Inhibitors; Diabetic Retinopathy; Double-Blind Method; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Male; Middle Aged; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
Topics: Aqueous Humor; Biological Availability; Chromatography, High Pressure Liquid; Diabetic Retinopathy; Drug Delivery Systems; Drug Implants; Fluocinolone Acetonide; Fluorescein Angiography; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Prospective Studies; Retina; Tandem Mass Spectrometry; Tomography, Optical Coherence; Visual Acuity; Vitreous Body | 2010 |
Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion.
Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluocinolone Acetonide; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide | 2011 |
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Topics: Diabetic Retinopathy; Double-Blind Method; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Prospective Studies; Retina; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitreous Body | 2011 |
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Topics: Cataract; Diabetic Retinopathy; Double-Blind Method; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Prospective Studies; Recurrence; Retina; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitreous Body | 2011 |
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
Topics: Drug Implants; Drug Therapy, Combination; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Panuveitis; Prednisone; Quality of Life; Sickness Impact Profile; Treatment Outcome; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity; Visual Fields | 2011 |
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.
Topics: Adult; Aged; Cross-Sectional Studies; False Positive Reactions; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Longitudinal Studies; Macular Edema; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Retina; Sensitivity and Specificity; Sensory Thresholds; Tomography, Optical Coherence; Uveitis; Visual Acuity | 2011 |
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Topics: Antihypertensive Agents; Cataract; Diabetic Retinopathy; Double-Blind Method; Drug Implants; Fluocinolone Acetonide; Fluorescein Angiography; Follow-Up Studies; Glaucoma; Glucocorticoids; Humans; Macular Edema; Phacoemulsification; Tomography, Optical Coherence; Trabeculectomy; Treatment Outcome; Visual Acuity; Vitreous Body | 2012 |
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
Topics: Aqueous Humor; Chromatography, High Pressure Liquid; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Mass Spectrometry; Prospective Studies; Uveitis | 2013 |
78 other study(ies) available for fluocinolone acetonide and Central Retinal Edema, Cystoid
| Article | Year |
|---|---|
Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes.
Topics: Cataract; Dexamethasone; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema | 2023 |
Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Follow-Up Studies; Glaucoma; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Treatment Outcome; Uveitis; Visual Acuity | 2022 |
Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Prospective Studies; Steroids; Visual Acuity | 2022 |
Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
Topics: Cohort Studies; Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Visual Acuity | 2022 |
Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Visual Acuity | 2022 |
[Not quite an intraocular UFO: An IFO, "Iluvien floating object"].
Topics: Diabetic Retinopathy; Fluocinolone Acetonide; Humans; Ifosfamide; Macular Edema | 2022 |
Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Iris; Macular Edema; Retrospective Studies | 2023 |
The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Prospective Studies; Retrospective Studies | 2023 |
Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Treatment Outcome | 2023 |
Alternative technique for the injection of fluocinolone acetonide (FAc) intravitreal implant (Iluvien
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male | 2023 |
[Comparison of available clinical and imaging tools to assess good positioning of a fluocinolone acetonide implant (Iluvien®) in the vitreous cavity after injection].
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies | 2023 |
Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data.
Topics: Diabetic Retinopathy; Drug Implants; Endothelial Growth Factors; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Pilot Projects; Tomography, Optical Coherence; Visual Field Tests | 2023 |
The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Macular Edema | 2023 |
INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY: Report of Preliminary Findings.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies | 2023 |
Treatment of Iluvien® malposition with YAG laser: A case study approach.
Topics: Diabetic Retinopathy; Fluocinolone Acetonide; Humans; Lasers, Solid-State; Macular Edema; Treatment Outcome | 2023 |
BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema | 2023 |
INJECTABLE FLUOCINOLONE IMPLANT FOR THE MANAGEMENT OF CHRONIC POSTSURGICAL CYSTOID MACULAR EDEMA IN VITRECTOMIZED EYES.
Topics: Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Retrospective Studies | 2023 |
Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases.
Topics: Dexamethasone; Fluocinolone Acetonide; Glaucoma; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Intravitreal Injections; Macular Edema; Ocular Hypertension; Retinal Diseases; Retrospective Studies; Triamcinolone Acetonide | 2023 |
SPONTANEOUS FORMATION AND RESOLUTION OF A LAMELLAR HOLE IN A PATIENT SUCCESSFULLY TREATED FOR DIABETIC MACULAR EDEMA WITH A FLUOCINOLONE ACETONIDE IMPLANT.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Fluocinolone Acetonide; Humans; Macular Edema; Male; Middle Aged; Retina; Retinal Perforations | 2023 |
Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months.
Topics: Diabetic Retinopathy; Eye Infections, Bacterial; Female; Fluocinolone Acetonide; Glaucoma; Humans; Macular Edema; Male; Prospective Studies; Uveitis | 2023 |
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Topics: Aged; Bevacizumab; Dexamethasone; Diabetic Retinopathy; Drug Administration Schedule; Drug Implants; Drug Substitution; Female; Fluocinolone Acetonide; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2020 |
The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Topics: Aged; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome; Visual Acuity | 2020 |
The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Topics: Aged; Cohort Studies; Diabetic Retinopathy; Drug Implants; Ethnicity; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Incidence; Macular Edema; Male; Retina; Retrospective Studies; Tomography, Optical Coherence; United Kingdom; Visual Acuity | 2021 |
Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
Topics: Adult; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Panuveitis; Recurrence; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Uveitis, Intermediate; Uveitis, Posterior; Visual Acuity | 2020 |
Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Vascular Endothelial Growth Factor A; Visual Acuity | 2020 |
Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retina; Visual Acuity | 2020 |
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Topics: Aged; Diabetic Retinopathy; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Time Factors; Treatment Outcome; Visual Acuity | 2021 |
Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study.
Topics: Aged; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Retina; Retrospective Studies; Visual Acuity | 2020 |
Treatment of radiation-induced maculopathy with fluocinolone acetonide.
Topics: Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Retinal Diseases; Visual Acuity | 2020 |
Effects of Long-Term DME Control With 0.2 µg/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Quality of Life; Visual Acuity | 2020 |
Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis.
Topics: Birdshot Chorioretinopathy; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Visual Acuity | 2022 |
Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; United Arab Emirates; Visual Acuity | 2021 |
Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Topics: Aged; Dexamethasone; Diabetic Retinopathy; Female; Fluocinolone Acetonide; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2021 |
The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
Topics: Dexamethasone; Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Steroids; Visual Acuity | 2021 |
Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant.
Topics: Biomarkers; Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity | 2021 |
Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retina; Retrospective Studies | 2022 |
Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Retrospective Studies; Visual Acuity | 2021 |
Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Retrospective Studies; United Kingdom | 2022 |
[Intraoperative photo of fluocinolone acetonide and dexamethasone implants].
Topics: Dexamethasone; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema | 2021 |
Removal of a migrated dexamethasone implant (Ozurdex) from the anterior chamber using an intravenous cannula.
Topics: Aged; Anterior Chamber; Cannula; Dexamethasone; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema | 2021 |
Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
Topics: Aged; Diabetic Retinopathy; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Retrospective Studies; Time Factors; Treatment Outcome; United Kingdom; Visual Acuity | 2017 |
Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Topics: Aged; Cohort Studies; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Visual Acuity | 2017 |
Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema.
Topics: Aged; Cost-Benefit Analysis; Dexamethasone; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Vascular Endothelial Growth Factor A | 2017 |
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
Topics: Aged; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Visual Acuity | 2017 |
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
Topics: Aged; Cohort Studies; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Visual Acuity | 2017 |
ILUVIEN in Diabetic Macular Edema: The Choice of Second-Line Corticosteroid Should Be Left to the Clinical Judgement of the Treating Physician.
Topics: Clinical Trials as Topic; Diabetic Retinopathy; Dose-Response Relationship, Drug; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Practice Patterns, Physicians'; Treatment Outcome | 2018 |
Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Topics: Aged; Chronic Disease; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Visual Acuity; Vitrectomy | 2018 |
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retina; Retrospective Studies; United Kingdom; Visual Acuity | 2018 |
Fluocinolone acetonide intravitreal implant (Retisert
Topics: Adolescent; Adult; Arthritis, Juvenile; Child; Child, Preschool; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Macula Lutea; Macular Edema; Male; Tomography, Optical Coherence; Uveitis; Visual Acuity; Young Adult | 2018 |
BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
Topics: Aged; Basement Membrane; Drug Implants; Endotamponade; Epiretinal Membrane; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Visual Acuity; Vitrectomy | 2021 |
Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Topics: Aged; Diabetic Retinopathy; Drug Implants; Europe; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Visual Acuity | 2019 |
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Topics: Cost-Benefit Analysis; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Quality-Adjusted Life Years; United Kingdom | 2019 |
Inadvertent Subconjunctival Injection of a Fluocinolone Acetonide Implant.
Topics: Conjunctival Diseases; Drug Implants; Eye Foreign Bodies; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Medical Errors; Middle Aged | 2019 |
Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Topics: Aged; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Germany; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Middle Aged; Retrospective Studies; Tonometry, Ocular; Visual Acuity | 2020 |
Inadvertent Expulsion of Fluocinolone Acetonide Intravitreal Implant during Pars Plana Vitrectomy.
Topics: Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraoperative Complications; Intravitreal Injections; Macular Edema; Middle Aged; Uveitis; Vitrectomy | 2018 |
Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration.
Topics: Aged; Anti-Inflammatory Agents; Diabetic Retinopathy; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Logistic Models; Macular Edema; Male; Middle Aged; Pilot Projects; Retinal Degeneration; Retrospective Studies; Tomography, Optical Coherence | 2019 |
ANTERIOR MIGRATION OF INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANTS: A CASE REPORT.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Foreign-Body Migration; Humans; Macular Edema; Male; Middle Aged; Retrospective Studies | 2022 |
Early treatment response of fluocinolone (retisert) implantation in patients with uveitic macular edema: an optical coherence tomography study.
Topics: Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Retina; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Uveitis; Visual Acuity | 2013 |
Spontaneous dislocation of fluocinolone acetonide implant pellets from their suture struts.
Topics: Adolescent; Adult; Aged; Child; Device Removal; Drug Implants; Equipment Failure; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Retrospective Studies; Sutures; Uveitis; Visual Acuity; Vitreous Body | 2015 |
Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
Topics: Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Humans; Intravitreal Injections; Macular Edema; Markov Chains; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2015 |
Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Male; Middle Aged; Patient Selection; Retina; Retrospective Studies; Treatment Outcome; Visual Acuity | 2016 |
Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes.
Topics: Diabetic Retinopathy; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Tomography, Optical Coherence; Vitrectomy | 2016 |
Comments on 'Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Macular Edema; Triamcinolone Acetonide; Visual Acuity; Vitreous Body | 2016 |
Introduction.
Topics: Academies and Institutes; Consensus Development Conferences as Topic; Databases, Factual; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Ophthalmology; United States; Vitreous Body | 2016 |
Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Ophthalmology; United States; Vascular Endothelial Growth Factor A; Vitreous Body | 2016 |
[French practice patterns in the management of diabetic macular edema].
Topics: Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Fluocinolone Acetonide; France; Humans; Intravitreal Injections; Macular Edema; Practice Patterns, Physicians'; Ranibizumab; Surveys and Questionnaires; Vascular Endothelial Growth Factor A | 2016 |
Fluocinolone Acetonide Intravitreal Implant in the Visual Axis.
Topics: Diabetic Retinopathy; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Laser Therapy; Lasers, Solid-State; Macular Edema; Male; Middle Aged; Vision Disorders | 2016 |
Iluvien Implantation for Uveitis and Uveitic Macular Edema.
Topics: Adult; Drug Implants; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Tomography, Optical Coherence; Uveitis; Visual Acuity; Vitreous Body | 2018 |
Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Topics: Aged; Diabetic Retinopathy; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Preoperative Period; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy | 2017 |
Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Topics: Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; United Kingdom; Visual Acuity | 2017 |
Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Dose-Response Relationship, Drug; Drug Implants; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Tomography, Optical Coherence; United Kingdom; Visual Acuity | 2017 |
Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Topics: Chronic Disease; Drug Delivery Systems; Drug Implants; Female; Fluocinolone Acetonide; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Pilot Projects; Prospective Studies; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitreous Body | 2008 |
PSivida corporation.
Topics: Brachytherapy; Drug Delivery Systems; Drug Implants; Drug Industry; Eye Diseases; Fluocinolone Acetonide; Humans; Macular Edema; Neoplasms | 2008 |
Fluocinolone acetonide implant (Retisert) for chronic cystoid macular edema in two patients with AIDS and a history of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Chronic Disease; Cytomegalovirus Retinitis; Drug Implants; Fluocinolone Acetonide; Follow-Up Studies; Glucocorticoids; Humans; Immune Reconstitution Inflammatory Syndrome; Macular Edema; Male; Medical Records; Middle Aged; Uveitis | 2011 |
A functional, nonfunctioning Retisert implant.
Topics: Aged; Anti-Inflammatory Agents; Device Removal; Drug Implants; Equipment Failure; Eye Diseases; Female; Fluocinolone Acetonide; Humans; Inflammation; Macular Edema; Retreatment; Treatment Outcome; Vitreous Body | 2011 |
Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.
Topics: Aged; Cataract Extraction; Chronic Disease; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Studies; Fovea Centralis; Glucocorticoids; Humans; Intraocular Pressure; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Vein Occlusion; Trabeculectomy; Visual Acuity; Vitreous Body | 2012 |
Retisert (Bausch & Lomb/Control Delivery Systems).
Topics: Animals; Anti-Inflammatory Agents; Choroidal Neovascularization; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Implants; Fluocinolone Acetonide; Humans; Macular Edema; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Uveitis, Posterior | 2005 |
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
Topics: Aged; Antiviral Agents; Behcet Syndrome; Cytomegalovirus Retinitis; Drug Implants; Fluocinolone Acetonide; Foscarnet; Ganciclovir; Glucocorticoids; Humans; Immunocompromised Host; Macular Edema; Male; Retrospective Studies; Uveitis | 2007 |